Bavarian Nordic — Februar 2020
-
Zealand Pharma: Wellington øger sin ejerandel
14:12
Storinvestoren Wellington Management Group øger investeringen i det danske biotekselskab Zealand Pharma til 5,03 pct. og 5,07 pct. inklusive 0,04 pct. i finansielle instrumenter.Det skriver Zealand Pharma i en fondsbørsmeddelelse.
Fra 31. januar til 4. februar ejede Wellington Management 4,99 pct. af det danske selskab samt 0,04 pct. i finansielle instrumenter, hvilket giver en samlet ejerandel på 5,04 pct., skriver Zealand Pharma.
-
Vi har været massivt attack. Beklager nedetiden.
-
-
Coronavirus: Gilead’s Remdesivir Begins Trials as Researchers Publish Positive In Vitro Results
Clinical trials of Gilead Sciences’ remdesivir have begun in Wuhan, China, the center of the novel coronavirus outbreak, a day after Chinese researchers recommended that the antiviral drug candidate remdesivir be assessed in humans as a potential treatment for 2019-nCoV.
GEN - Genetic Engineering and Biotechnology News (www.genengnews.com)
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind